Elysium Health

Elysium Health is an American health and wellness company headquartered in New York City. Founded in 2014 by Leonard Guarente, Dan Alminana, and Eric Marcotulli, the company developed a consumer-facing business around nutritional supplements and biological-aging research. Its products are positioned at the intersection of longevity science, preventive health, and personalized measurement rather than conventional disease treatment. The company’s first major product was Basis, introduced in 2015. Basis combines nicotinamide riboside, a precursor associated with cellular NAD+ metabolism, with pterostilbene, a compound related to resveratrol. Elysium presented the formulation as a way to support cellular and metabolic processes associated with aging. The product helped establish the company’s identity as a science-oriented longevity brand, while also placing it in a commercially competitive and legally contested market for NAD-related ingredients and supplements. Elysium obtained $20 million in Series B financing in December 2016. Its business subsequently broadened beyond a single longevity supplement. In 2019, it introduced Index, a saliva-based epigenetic test intended to estimate biological age. The product reflected Elysium’s effort to connect supplementation with measurement and personal health data, although an epigenetic age estimate is not equivalent to a clinical diagnosis or a direct measure of remaining lifespan. The company expanded its product portfolio during the 2020s. Matter, launched in June 2020, was marketed around brain health and the preservation of cognitive function. Format, introduced in October 2021, was associated with healthy aging, immune support, and broader wellness claims. Mosaic followed in 2023 with a focus on skin aging and collagen protection. In October 2024, Elysium introduced Vision, a daily product positioned around macular health and eye longevity. Elysium’s public profile has also been shaped by disputes over the sourcing and patent position of nicotinamide riboside. ChromaDex, a supplier connected to Basis ingredients, and Dartmouth College brought patent litigation against Elysium in 2018. W. R. Grace and Company filed a separate patent case in 2020. The Dartmouth and ChromaDex claims were dismissed by a federal district court in 2021, and the United States Court of Appeals for the Federal Circuit affirmed the judgment in 2023, holding the asserted claims invalid under 35 U.S.C. § 101. These disputes are an important part of Elysium’s corporate history because they illustrate the intellectual-property competition surrounding longevity supplements. Elysium Health remains best understood as a direct-to-consumer, science-led supplement and testing brand. Its market proposition emphasizes research, proprietary formulations, and measurable aspects of aging, while its products remain dietary supplements or consumer tests rather than replacements for medical care. Publicly available reference material does not establish a parent company, exchange listing, ticker, or a complete current executive roster.

Elysium Health was established in 2014 by Leonard Guarente, Dan Alminana, and Eric Marcotulli in New York City. The founders built the company around translating research on aging biology into products sold directly to consumers. Rather than operating primarily as a pharmaceutical developer, Elysium adopted the dietary-supplement model and emphasized scientific formulation, research partnerships, and consumer education about longevity. The company’s first product, Basis, arrived in 2015. Its formulation contained nicotinamide riboside and pterostilbene, ingredients associated with cellular metabolism and antioxidant research. Basis gave Elysium a distinctive position in the emerging longevity market, but the ingredients also connected the company to disputes over supply agreements, commercial disclosures, and patent rights. ChromaDex had supplied ingredients used in Basis and later became a litigant in a broader conflict over nicotinamide riboside technology and patents. Elysium raised $20 million in Series B financing in December 2016. The funding supported the company’s expansion as it sought to develop a broader platform rather than rely on one supplement. In 2019, Elysium introduced Index, a test using epigenetic analysis of saliva samples to estimate biological age. Index extended the company’s proposition from taking supplements to monitoring a biological-age-related metric, although such estimates should not be confused with clinical diagnoses. The portfolio expanded further in the 2020s. Matter launched in June 2020 with claims and positioning related to brain health, cognitive maintenance, and slowing brain aging or atrophy. In October 2021, the company launched Format, associated with healthy aging and immune-system support. Mosaic, introduced in 2023, addressed skin aging and collagen protection. In October 2024, Vision broadened the range into eye wellness, with a focus on macular health and eye longevity. Litigation has been a significant part of the company’s history. In September 2018, Dartmouth College and ChromaDex sued Elysium for alleged infringement of patents involving nicotinamide riboside. The dispute followed earlier commercial dealings between Elysium and ChromaDex, including the supply of ingredients for Basis. In August 2020, W. R. Grace and Company filed another case concerning patents for crystalline nicotinamide riboside. In September 2021, a federal district court dismissed the Dartmouth and ChromaDex claims and effectively invalidated the patents at issue. In February 2023, the Federal Circuit affirmed the district court’s judgment, concluding that the asserted claims were invalid under section 101 of the U.S. patent statute. Elysium’s development reflects the wider commercialization of longevity science. Its products cover cellular aging, cognition, immune-related wellness, skin, and eye health, while Index provides a measurement-oriented service. The company’s public materials and product categories position it as a research-led consumer-health brand. Available reference material does not establish a public listing, ticker, parent company, or sufficiently documented current executive team.

1. 2024Vision introduced

   Elysium introduced Vision as a daily product for macular health and eye longevity.

   Source
2. 2023Mosaic launched

   Elysium introduced Mosaic for skin-aging and collagen-related support.

   Source
3. 2021Format launched

   Format joined the portfolio with positioning related to anti-aging and immune support.

   Source
4. 2020Matter launched

   Elysium introduced Matter as a brain-health and healthy-aging supplement.

   Source
5. 2019Index launched

   Elysium introduced Index, an epigenetic saliva test intended to estimate biological age.

   Source
6. 2016Series B financing

   The company received $20 million in Series B funding.

   Source
7. 2015Basis introduced

   Elysium launched Basis, its first product, containing nicotinamide riboside and pterostilbene.

   Source
8. 2014Company founded

   Leonard Guarente, Dan Alminana, and Eric Marcotulli founded Elysium Health in New York City.

   Source

A science-oriented longevity and preventive-wellness brand combining dietary supplements with biological-age measurement and products aimed at cellular, cognitive, immune, skin, and eye health.

• BasisLongevity dietary supplement2015

  Elysium’s first major supplement, launched in 2015. Basis contains nicotinamide riboside and pterostilbene and is positioned around cellular energy, NAD+ metabolism, and healthy aging. Its ingredients became central to later commercial and patent disputes involving Elysium and other companies.

• IndexBiological-age test2019

  A saliva-based test introduced in 2019 that uses epigenetic analysis to estimate biological age. Index represents Elysium’s effort to pair its supplement business with a consumer-facing measurement of an aging-related biological signal.

• MatterBrain-health supplement2020

  Launched in June 2020, Matter is positioned around maintaining brain health and supporting cognitive longevity. Public descriptions associate it with efforts to slow or mitigate aspects of brain aging and atrophy.

• FormatHealthy-aging supplement2021

  Introduced in October 2021, Format is associated with anti-aging and immune-system support. It extends Elysium’s product range beyond the cellular-aging emphasis of Basis into broader daily wellness positioning.

• MosaicSkin-health supplement2023

  A daily supplement launched in 2023 and positioned around preventing or reducing visible skin aging and protecting collagen. It represents Elysium’s expansion into beauty-from-within and connective-tissue wellness.

• VisionEye-health supplement2024

  Introduced in October 2024, Vision is a daily product positioned to support macular health and promote eye longevity. It broadens the portfolio into age-related eye wellness.

• 2023Federal Circuit patent rulingOther

  Patent litigation involving Dartmouth College, ChromaDex, and Elysium concerned claims related to nicotinamide riboside.

  What changed. The Federal Circuit affirmed the lower court’s judgment that the asserted claims were invalid under 35 U.S.C. § 101.

  Aftermath. The ruling upheld Elysium’s success in that patent dispute.

  Source
• 2021Launch of FormatProduct launch

  The company sought to offer a broader daily healthy-aging and immune-support product.

  What changed. Elysium introduced Format in October 2021.

  Aftermath. Format expanded the brand’s consumer-health portfolio beyond Basis and Matter.

  Source
• 2020Launch of MatterProduct launch

  Elysium broadened its portfolio into cognitive and brain-aging support.

  What changed. The company launched Matter as a supplement associated with brain health and healthy aging.

  Aftermath. Matter added a neuro-wellness category to the company’s product range.

  Source
• 2019Launch of IndexProduct launch

  Elysium expanded beyond supplementation into consumer measurement of aging-related biological signals.

  What changed. The company introduced an epigenetic saliva test intended to estimate biological age.

  Aftermath. Index broadened Elysium’s longevity proposition toward testing and personalized health information.

  Source
• 2015Launch of BasisProduct launch

  Elysium sought to establish a consumer longevity brand with a supplement centered on nicotinamide riboside and pterostilbene.

  What changed. The company introduced Basis as its first product.

  Aftermath. Basis became the product at the center of later supplier and patent disputes involving nicotinamide riboside.

  Source

• 2024Elysium introduces Vision

  Vision was introduced as a daily supplement positioned around macular health and eye longevity.

  Product launch
  Source
• 2023Federal Circuit affirms invalidity ruling in Elysium patent case

  The United States Court of Appeals for the Federal Circuit affirmed the district court’s judgment that the relevant patent claims were invalid under 35 U.S.C. § 101.

  Lawsuit
  Source
• 2023Elysium launches Mosaic

  Mosaic was introduced as a daily supplement focused on skin aging and collagen protection.

  Product launch
  Source
• 2021Court dismisses Dartmouth and ChromaDex patent claims

  A United States district judge dismissed the Dartmouth and ChromaDex claims, finding the asserted patents invalid.

  Lawsuit
  Source
• 2021Elysium launches Format

  Format entered the portfolio as a daily product associated with anti-aging and immune-system support.

  Product launch
  Source
• 2020W. R. Grace files patent case against Elysium

  W. R. Grace and Company sued Elysium over patents concerning crystalline nicotinamide riboside.

  Lawsuit
  Source
• 2020Elysium launches Matter

  Matter was introduced as a supplement positioned around brain health and slowing aspects of brain aging or atrophy.

  Product launch
  Source
• 2019Elysium launches Index biological-age test

  The company introduced a saliva-based epigenetic test designed to estimate biological age.

  Product launch
  Source
• 2018Dartmouth and ChromaDex sue Elysium over nicotinamide riboside patents

  Dartmouth College and ChromaDex filed patent-infringement litigation concerning nicotinamide riboside used in the Basis product.

  Lawsuit
  Source
• 2016Elysium Health raises Series B financing

  Elysium Health received $20 million in Series B funding as it expanded its longevity-supplement business.

  Other
  Source

1. Elysium Health
2. Elysium Health official website